Chapter 1

Aim and Outline of the Thesis

Harald Engelhardt\textsuperscript{1,2}

\textsuperscript{1} Boehringer Ingelheim RCV GmbH & Co KG, Department of Medicinal Chemistry, Dr. Boehringerstrasse 5-11, Vienna, Austria

\textsuperscript{2} Amsterdam Institute of Molecules, Medicines & Systems, Division of Medicinal Chemistry, Department of Chemistry and Pharmaceutical Sciences, Faculty of Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, the Netherlands
Aim and outline of the thesis

Chapter 1

**Aim of the thesis**

Shortly after the discovery of the fourth histamine receptor, abbreviated as $\text{H}_4\text{R}$, the search for potent and selective ligands was initiated.$^{1-5}$ Such ligands are essential to investigate the pharmacological properties of the newly discovered receptor. Expression profiles can provide a first hint as to the role of the receptor. E.g. the expression of the $\text{H}_4\text{R}$ on various cells of the immune system would suggest a role in inflammation and immunity.$^{6-9}$ However, the relative importance can only be assessed with selective agonists and antagonists that will enable appropriately designed *in vitro* and *in vivo* studies.

The design of such ligands is facilitated by the detailed knowledge of the essential receptor-ligand interactions as well as the concomitant shape requirements for the ligand. The structure of the $\text{H}_4\text{R}$ has not been solved to date. However, it belongs to the class of G-Protein coupled receptors (GPCR) for which structural information on related receptors is available.$^{10-12}$ The field of GPCRs has evolved rapidly and for advancing the field, Brian Kobilka and Robert Lefkowitz were rewarded with the 2012 Nobel Prize of Chemistry. The quality of a homology model not only depends on the availability of structural information on homologous receptors$^{10-12}$ but also on the availability of selective and chemically diverse ligands.

It is clear that the availability of potent selective $\text{H}_4\text{R}$ ligands that can be used in pharmacological and computational studies is a key factor to be able to advance the field of $\text{H}_4\text{R}$ research. We therefore set out to design and prepare new $\text{H}_4\text{R}$ ligands:

I. that posses improved physicochemical and DMPK properties in rodents to enable *in vivo* studies.

II. To generate a chemically diverse set of $\text{H}_4\text{R}$ ligands to facilitate the design of a comprehensive overview of key structural features of $\text{H}_4$-ligands and their receptor.
Outline of thesis

This thesis explores the chemical diversity of new H₄R ligands. In chapter 2 the status of the H₄R field is described at the time the work was initiated and an overview of the existing compound classes is provided. Chapter 3 discusses the SAR of several new indolecarboxamides. The data enable the definition of a predictive QSAR model that allowed the identification of several compounds with an activity comparable to the current standard JNJ-7777120. Some of the new analogs are not only excellently soluble, but display, in addition, a significantly increased half-life in mouse liver microsomes. Moreover, the current studies also provide valuable information on the receptor ligand interactions between the indolecarboxamides and the H₄R protein. Chapter 4 focuses on the elucidation of the binding mode of 2-aminopyrimidine ligands in the histamine H₄R. By combining SAR, protein–ligand modeling studies, and quantum mechanical calculations, we provide new insight into the molecular determinants of H₄R–ligand binding and propose ligand binding conformations and orientations in the H₄R binding pocket. In chapter 5 we designed and synthesized 4-(4-methylpiperazin-1-yl)-6-phenyl-2-vinylpyrimidine (VUF14480) as a covalent binder which interact with C98³,³⁶ in TM3. The covalent interaction of VUF14480 with C98³,³⁶ confirmed our previously proposed 2-aminopyrimidine binding pose. In chapter 6 we set out to investigate whether mild basic 2-aminopyrimidines in combination with the appropriate linker can serve as a replacement for the methylpiperazine moiety known to be essential in several compound classes. Not only have we discovered highly potent compounds, the correct methylpiperazine replacement results in compounds with improved metabolic properties. Combining the derived SAR with homology modelling leads to new detailed insights in the molecular aspects of ligand-H₄R binding in general, and specifically to the binding mode of the described bispyrimidines. Chapter 7 is dedicated to the search for a new H₄R ligand series to increase the diversity of compounds in the low-risk physicochemical property area (low ClogP, one basic center with a medium pKₐ). A new promising series, the triazoloquinoxalines, which has a good H₄R affinity with pKᵢ values up to 7.5, in combination with an acceptable metabolic stability, solubility and lipophilicity are identified. The SAR generated for this type of compounds allows the establishment of a reliable binding model in the H₄R.
Finally, in chapter 8 an overview of the properties of selected compounds, their relative binding relationship, as well as an outlook of future H₄ research is provided.

References


